alpelisib

CHEBI:CHEBI_747597

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2680140
generic_name
alpelisib
dosage_form
GRANULE
product_type
HUMAN PRESCRIPTION DRUG
marketing_category
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
route
ORAL
active_ingredient_strength
125 mg/1
marketing_start_date
20220405
package_marketing_start_date
24-MAY-19
labeler_name
Novartis Pharma Stein AG
manufacturer_name
Novartis Pharmaceuticals Corporation
product_ndc
0078-1175
spl_id
585121b9-5641-4a5b-b152-2eb30bc0fde0
active_ingredient_name
ALPELISIB
package_ndc
0078-1175-51
package_description
28 PACKET in 1 CARTON (0078-1175-51) / 1 GRANULE in 1 PACKET (0078-1175-19)
brand_name
VIJOICE
brand_name_base
VIJOICE
application_number
NDA218466
unii
08W5N2C97Q
spl_set_id
638069a4-aee0-46c9-9e21-54ad449c163c
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class